OCULAR THERAPEUTIX IN
9.0900
25-November-24 16:45:01
15 minutes delayed
Stocks
+0.2600
+2.94%
Today's range
8.7795 - 9.1300
ISIN
N/A
Source
NASDAQ
-
Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights
14 Nov 2024 07:00:01 By Nasdaq GlobeNewswire
-
13 Nov 2024 07:30:00 By Nasdaq GlobeNewswire
-
Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer
12 Nov 2024 07:30:00 By Nasdaq GlobeNewswire
-
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
06 Nov 2024 07:30:00 By Nasdaq GlobeNewswire
-
NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK
28 Oct 2024 10:00:04 By NetDania Notify
-
NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK
21 Oct 2024 09:47:37 By NetDania Notify
-
NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK
16 Oct 2024 15:33:40 By NetDania Notify
-
15 Oct 2024 07:30:00 By Nasdaq GlobeNewswire
-
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09 Oct 2024 16:05:00 By Nasdaq GlobeNewswire
-
Ocular Therapeutix™ to Present at October Ophthalmology Meetings
09 Oct 2024 07:30:00 By Nasdaq GlobeNewswire
-
Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024
25 Sep 2024 07:30:00 By Nasdaq GlobeNewswire
-
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12 Sep 2024 16:05:00 By Nasdaq GlobeNewswire
-
Ocular Therapeutix™ to Present at September Retina Meetings
05 Sep 2024 07:30:00 By Nasdaq GlobeNewswire
-
Ocular Therapeutix™ to Present at Two Investor Conferences in September
04 Sep 2024 07:30:00 By Nasdaq GlobeNewswire
-
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Aug 2024 07:30:00 By Nasdaq GlobeNewswire
-
Ocular Therapeutix™ Reports Second Quarter 2024 Results
07 Aug 2024 07:10:00 By Nasdaq GlobeNewswire
-
07 Aug 2024 07:00:00 By Nasdaq GlobeNewswire
-
Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024
31 Jul 2024 07:30:00 By Nasdaq GlobeNewswire
-
Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study
30 Jul 2024 07:30:00 By Nasdaq GlobeNewswire
-
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 Jul 2024 16:05:00 By Nasdaq GlobeNewswire
- <<
- <
- 1
- >